Infant Bacterial Therapeutics AB logo

IBT TR B - Infant Bacterial Therapeutics AB Share Price

SEK2.19 0.0  0.0%

Last Trade - 26/01/18

Sector
Healthcare
Size
Small Cap
Market Cap £103.6m
Enterprise Value £67.5m
Revenue £n/a
Position in Universe th / 1850
Bullish
Bearish
Unlock IBT TR B Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.16 0.24 0.000 0.000 0.000 133.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, InfantBacterial Therapeutics AB revenues was not reported. Netloss increased 55% to SEK72M. Higher net loss reflectsResearch and development costs increase of 53% to SEK72.2M(expense), Total Financial Income decrease of 87% toSEK214K (income). Basic Earnings per Share excludingExtraordinary Items decreased from -SEK4.13 to -SEK6.41.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IBT TR B Revenue Unlock IBT TR B Revenue

Net Income

IBT TR B Net Income Unlock IBT TR B Revenue

Normalised EPS

IBT TR B Normalised EPS Unlock IBT TR B Revenue

PE Ratio Range

IBT TR B PE Ratio Range Unlock IBT TR B Revenue

Dividend Yield Range

IBT TR B Dividend Yield Range Unlock IBT TR B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IBT TR B EPS Forecasts Unlock IBT TR B Revenue
Profile Summary

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since March 29, 2016
No. of Shareholders: n/a
No. of Employees: 9
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange OMX Nordic Exchange Stockholm (Dual Listing)
Shares in Issue 11,226,184
Free Float (0.0%)
Eligible for
ISAs
SIPPs
IBT TR B Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IBT TR B
Upcoming Events for IBT TR B
Frequently Asked Questions for Infant Bacterial Therapeutics AB
What is the Infant Bacterial Therapeutics AB share price?

As of 26/01/18, shares in Infant Bacterial Therapeutics AB are trading at SEK2.19, giving the company a market capitalisation of £103.6m. This share price information is delayed by 15 minutes.

How has the Infant Bacterial Therapeutics AB share price performed this year?

Shares in Infant Bacterial Therapeutics AB are currently trading at SEK2.19 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Infant Bacterial Therapeutics AB price has moved by % over the past year.

What are the analyst and broker recommendations for Infant Bacterial Therapeutics AB?

There are no analysts currently covering Infant Bacterial Therapeutics AB.

When will Infant Bacterial Therapeutics AB next release its financial results?

Infant Bacterial Therapeutics AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Infant Bacterial Therapeutics AB dividend yield?

Infant Bacterial Therapeutics AB does not currently pay a dividend.

Does Infant Bacterial Therapeutics AB pay a dividend?

Infant Bacterial Therapeutics AB does not currently pay a dividend.

When does Infant Bacterial Therapeutics AB next pay dividends?

Infant Bacterial Therapeutics AB does not currently pay a dividend.

How do I buy Infant Bacterial Therapeutics AB shares?

To buy shares in Infant Bacterial Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Infant Bacterial Therapeutics AB?

Shares in Infant Bacterial Therapeutics AB are currently trading at SEK2.19, giving the company a market capitalisation of £103.6m.

Where are Infant Bacterial Therapeutics AB shares listed? Where are Infant Bacterial Therapeutics AB shares listed?

Here are the trading details for Infant Bacterial Therapeutics AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: IBT TR B
What kind of share is Infant Bacterial Therapeutics AB?

We were not able to load our ranking data for Infant Bacterial Therapeutics AB

Is there a Infant Bacterial Therapeutics AB share price forecast 2021?

We were not able to load any forecast data for Infant Bacterial Therapeutics AB.

How can I tell whether the Infant Bacterial Therapeutics AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Infant Bacterial Therapeutics AB. Over the past six months, the relative strength of its shares against the market has been %. At the current price of SEK2.19, shares in Infant Bacterial Therapeutics AB are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Infant Bacterial Therapeutics AB PE Ratio?

We were not able to find PE ratio data for Infant Bacterial Therapeutics AB.

Who are the key directors of Infant Bacterial Therapeutics AB?

Infant Bacterial Therapeutics AB's management team is headed by:

Staffan Stromberg - CEO
Eamonn Connolly - VRD
Michael Owens - CTR
Anders Kronstrom - CTO
Paul Alhadeff - OTH
Sanjiv Sharma - DSL
Leif Gallo - GCN
Jin-Yu Lu - OTH
Peter Rothschild - CHM
Margareta Hagman - DRC
Daniel Mackey - CFO
Eva Iden - DRC
Anthon Jahreskog - DRC
Kristina Sjoblom Nygren - IND
Who are the major shareholders of Infant Bacterial Therapeutics AB?

Here are the top five shareholders of Infant Bacterial Therapeutics AB based on the size of their shareholding:

Similar to IBT TR B
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.